All Updates

All Updates

icon
Filter
Partnerships
Illumina partners with National Cancer Center Singapore to study the genomics of lymphoma
Precision Medicine
Jul 3, 2024
This week:
Partnerships
Qualcomm and Google partner to develop AI-driven automotive solutions
Auto Tech
Yesterday
Product updates
Meta AI releases LayerSkip to accelerate inference in LLMs
Generative AI Infrastructure
Yesterday
Funding
Freeform secures funding from NVIDIA's NVentures
Additive Manufacturing
Oct 22, 2024
Product updates
Flexxbotics announces compatibility with LMI Technologies for quality inspection
Smart Factory
Oct 22, 2024
Funding
Oxla raises USD 11 million in seed funding to drive commercialization
Data Infrastructure & Analytics
Oct 22, 2024
Product updates
Cohesity enhances Gaia, its AI assistant, with visual data exploration and expanded data sources
Data Infrastructure & Analytics
Oct 22, 2024
Product updates
Finzly launches FedNow service through BankOS platform in AWS marketplace
FinTech Infrastructure
Oct 22, 2024
Product updates
Runway launches Act-One for AI facial expression motion capture
Generative AI Applications
Oct 22, 2024
Product updates
Ideogram launches Canvas for image manipulation and generation
Generative AI Applications
Oct 22, 2024
Partnerships
UiPath partners with Inflection AI to integrate AI solutions for enterprises
Generative AI Applications
Oct 22, 2024
Precision Medicine

Precision Medicine

Jul 3, 2024

Illumina partners with National Cancer Center Singapore to study the genomics of lymphoma

Partnerships

  • Illumina has announced a research collaboration with the National Cancer Center Singapore (NCCS) to study the genomics of lymphoma among Asians.

  • Under the research agreement, the partners will use Illumina’s genome sequencing technology platforms, such as the NovaSeq 6000 to profile the genomes of young adult lymphoma patients from an Asian multiethnic cohort. The research is aimed toward helping in the diagnosis and treatment of the disease, including over 1,000 patients in Singapore.

  • Analyst QuickTake:  In early 2022, San Diego-based Illumina began working with the National Cancer Center Japan on a study of genomics of nasopharyngeal carcinoma in Asian patients. In this study, Illumina used its TruSight Oncology 500 ctDNA to do a genomic analysis of blood samples of up to 96 patients with nasopharynx cancer. The project was initiated as a part of a collaborative study under the Asian Clinical Trials Network for Cancers (ATLAS) project.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.